Your browser doesn't support javascript.
loading
Expression levels of UL16 binding protein 1 and natural killer group 2 member D affect overall survival in patients with gastric cancer following gastrectomy.
Kamei, Ryoji; Yoshimura, Kiyoshi; Yoshino, Shigefumi; Inoue, Moeko; Asao, Tetsuhiko; Fuse, Masanori; Wada, Satoshi; Kuramasu, Atsuo; Furuya-Kondo, Tomoko; Oga, Atsunori; Iizuka, Norio; Suzuki, Nobuaki; Maeda, Noriko; Watanabe, Yusaku; Matsukuma, Satoshi; Iida, Michihisa; Takeda, Shigeru; Ueno, Tomio; Yamamoto, Noboru; Fukagawa, Takeo; Katai, Hitoshi; Sasaki, Hiroki; Hazama, Shoichi; Oka, Masaaki; Nagano, Hiroaki.
Afiliação
  • Kamei R; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Yoshimura K; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Yoshino S; Experimental Therapeutics, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Inoue M; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Asao T; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Fuse M; Experimental Therapeutics, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Wada S; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Kuramasu A; Experimental Therapeutics, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Furuya-Kondo T; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Oga A; Experimental Therapeutics, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Iizuka N; Division of Cancer Immunotherapy, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Suzuki N; Division of Cancer Immunotherapy, Kanagawa Cancer Center, Yokohama, Kanagawa 241-8515, Japan.
  • Maeda N; Department of Molecular Pharmacology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Watanabe Y; Department of Molecular Pathology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Matsukuma S; Department of Molecular Pathology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Iida M; Department of KAMPO Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Hiroshima 734-0037, Japan.
  • Takeda S; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Ueno T; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Yamamoto N; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Fukagawa T; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Katai H; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Sasaki H; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Hazama S; Department of Gastroenterological, Breast and Endocrine Surgery, Yamaguchi University School of Medicine, Ube, Yamaguchi 755-8505, Japan.
  • Oka M; Experimental Therapeutics, National Cancer Center Hospital, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan.
  • Nagano H; Gastric Surgery Division, National Cancer Center Hospital, Chuo-ku, Tokyo 104-0045, Japan.
Oncol Lett ; 15(1): 747-754, 2018 Jan.
Article em En | MEDLINE | ID: mdl-29391893
ABSTRACT
UL16 binding protein 1 (ULBP1) expressed on the tumor cell surface binds to the natural killer group 2 member D (NKG2D) receptor presenting on natural killer (NK), cluster of differentiation (CD)8+ T, and γ δ T cells. However, the roles of ULBP1 and NKG2D expression and associated immune responses in gastric cancer are unclear. The present study investigated the associations between ULBP1 and NKG2D expression and clinical outcomes in patients with gastric cancer. The levels of ULBP1 and NKG2D expression were examined in human gastric cancer cell lines and gastric cancer tissues from 98 patients who underwent surgery from 2004 to 2008. MKN-74 cells expressed ULBP1 with ULBP2, -5, or -6. NKG2D was expressed at a higher level following activation of T cells and NK cells. Among the tissue sections positive for NKG2D expression, 6 patients were positive for CD8 and CD56. In all tissues, NKG2D-expressing cells were typically aCD8+ T cells. Patients with NKG2D expression in tumors exhibited significantly longer overall survival (OS) compared with patients without NKG2D expression in tumors (P=0.0217). The longest OS was observed in patients positive for ULBP1 and NKG2D, whereas the shortest OS was observed in patients negative for ULBP1 and NKG2D. The interaction between ULBP1 and NKG2D may improve OS in patients with gastric cancer, and may have applications in immunotherapy for the induction of adaptive immunity in patients with cancer. Additionally, ULBP1 and NKG2D may be useful as prognostic biomarkers in gastric cancer.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncol Lett Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Oncol Lett Ano de publicação: 2018 Tipo de documento: Article País de afiliação: Japão